Clinical, hematologic, and cytogenetic characteristics of 5q-deleted MDS patients
| . | Sex/age . | FAB . | BM blast . | Hb, g/L . | WBC, 109/L . | Plt, 109/L . | Karyotype . | Treatment . | |
|---|---|---|---|---|---|---|---|---|---|
| Ongoing . | Previous . | ||||||||
| Patients with 5q− syndrome | |||||||||
| 1 | F/73 | RA | < 5% | 110 | 7.5 | 211 | del(5)(q13q33) | Epo | — |
| 2 | F/73 | RA | < 5% | 72 | 2.8 | 275 | del(5)(q13q33) | — | — |
| 3 | F/83 | RA | < 5% | 76 | 5.3 | 426 | del(5)(q14) | — | — |
| 4 | F/82 | RA | < 5% | 102 | 4.7 | 439 | del(5)(q15-21) | — | — |
| 5 | M/75 | RA | < 5% | 151 | 8.9 | 189 | del(5)(q15) | G-CSF/Epo | — |
| Other MDS patients with 5q deletions | |||||||||
| 6 | M/73 | RAEB | 10% | 72 | 1.4 | 150 | del(5)(q23) | — | — |
| 7 | F/81 | RA | < 5% | 114 | 7.2 | 320 | del(5)(q22q35)del(6) | — | — |
| 8 | F/83 | RA | < 5% | 104 | 4.5 | 414 | del(5)(q13q33)del(20) | — | Epo |
| 9 | F/87 | RA | < 5% | 109 | 4.6 | 382 | del(5)(q13q33)+8 | — | — |
| 10 | F/83 | RAEB | 7% | 100 | 5.2 | 279 | del(5)(q*)del(11)del(2) | — | — |
| 11 | F/72 | RAEB | 17% | 101 | 9.9 | 201 | del(5)(q22)+8 | Prednisolone | — |
| 12 | F/68 | RAEB | 6% | 123 | 8.0 | 80 | del(5)(q15)+2mar | — | † |
| . | Sex/age . | FAB . | BM blast . | Hb, g/L . | WBC, 109/L . | Plt, 109/L . | Karyotype . | Treatment . | |
|---|---|---|---|---|---|---|---|---|---|
| Ongoing . | Previous . | ||||||||
| Patients with 5q− syndrome | |||||||||
| 1 | F/73 | RA | < 5% | 110 | 7.5 | 211 | del(5)(q13q33) | Epo | — |
| 2 | F/73 | RA | < 5% | 72 | 2.8 | 275 | del(5)(q13q33) | — | — |
| 3 | F/83 | RA | < 5% | 76 | 5.3 | 426 | del(5)(q14) | — | — |
| 4 | F/82 | RA | < 5% | 102 | 4.7 | 439 | del(5)(q15-21) | — | — |
| 5 | M/75 | RA | < 5% | 151 | 8.9 | 189 | del(5)(q15) | G-CSF/Epo | — |
| Other MDS patients with 5q deletions | |||||||||
| 6 | M/73 | RAEB | 10% | 72 | 1.4 | 150 | del(5)(q23) | — | — |
| 7 | F/81 | RA | < 5% | 114 | 7.2 | 320 | del(5)(q22q35)del(6) | — | — |
| 8 | F/83 | RA | < 5% | 104 | 4.5 | 414 | del(5)(q13q33)del(20) | — | Epo |
| 9 | F/87 | RA | < 5% | 109 | 4.6 | 382 | del(5)(q13q33)+8 | — | — |
| 10 | F/83 | RAEB | 7% | 100 | 5.2 | 279 | del(5)(q*)del(11)del(2) | — | — |
| 11 | F/72 | RAEB | 17% | 101 | 9.9 | 201 | del(5)(q22)+8 | Prednisolone | — |
| 12 | F/68 | RAEB | 6% | 123 | 8.0 | 80 | del(5)(q15)+2mar | — | † |
BM morphology and blood values of patients were investigated in connection with BM aspiration for the present studies. Patients 1-4, 6, and 9-11 were dependent on red cell transfusions at the time of the studies.
MDS indicates myelodysplastic syndromes; FAB, French-American-British classification; BM, bone marrow; RA, refractory anemia; RAEB, refractory anemia with excess blasts.
The specific breakpoints on the long arm of chromosome 5 could not be established in this patient.
GM-CSF plus tioguanin + ara-C + daunorubicin (see “Materials and methods”).